



## **CERTIFICATE OF ANALYSIS No.: 2021-7358**

## CLIENT

Pharmahemp d.o.o., Cesta v Gorice 8 1000 Ljubljana, Slovenija

## SAMPLE \* DR KENT CBD GLUCOSAMINE CREAM



Sample condition:	SUITABLE	Work order:	2021-106027	Sample received:	29/12/2021		
Sample ID:	2152026	Analysis ID:	2021_301	Start of analysis:	29/12/2021		
Sample type:	Paste	Method ID:	PHL_RPC_12C	End of analysis:	30/12/2021		
Batch No.: *	KCG00521356A	Method SOP:	MET-002-03	Analyst:	Karmen Korbar		
* Information provided by the client.							

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV - Cannabidivarin	< LOQ	n/a	
CBDA - Cannabidiolic acid	0.271	0.046	
CBGA - Cannabigerolic acid	< LOQ	n/a	
CBG - Cannabigerol	< LOQ	n/a	
CBD - Cannabidiol	0.326	0.049	
THCV - Tetrahydrocannabivarin	< LOQ	n/a	
CBN - Cannabinol	< LOQ	n/a	
CBC - Cannabichromene	< LOQ	n/a	
<b>THC</b> - Δ-9-Tetrahydrocannabinol	< LOQ	n/a	
THCA - $\Delta$ -9-Tetrahydrocannabinolic acid	< LOQ	n/a	
8-THC - Δ-8-Tetrahydrocannabinol	< LOQ #	n/a	
CBL - Cannabicyclol	< LOQ #	n/a	

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

Approved by:

30/12/2021

End of Certificate

VUN mag. Mako Dragan

Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar Chief Technology Officer